Rottenstein Law Group Notes With Approval Facebook Decision to Withdraw Special Privileges From Drugmakers

PRWEB.COM Newswire (PRWEB) August 24, 2011

According to an article at DailyTech, Facebook has reversed an earlier policy decision to exempt the pages of pharmaceutical companies from public comments. Now those pages, like all others, will be open to all comments from other Facebook users. The policy reversal is prompting the pharmaceutical companies to take down their Facebook pages.

“It took years for the pharmaceutical companies to create Facebook pages because they feared users could write negative statements about their products all over their page Walls,” according to the article. “Also, these companies were worried that users could write about bad side effects and encourage/advertise off-label use. Facebook finally gave them the exclusive ability to block public comments on their page Walls.”

Now, however, Facebook is disallowing the blocking of public comments, and the drug companies are “not happy about it.” Facebook noted that it will allow some companies to continue blocking public comments, but most will lose this privilege. The companies that will become open are those focused on the company itself or “patient-specific communities.”

“Companies who don’t delete their Facebook [pages] worry that they’ll have to use additional resources to monitor their page Walls on a daily basis,” the article explained. “The reason for constant monitoring is their fear of adverse event reports (AERs), which would be a result of a user posting about a negative reaction to a certain company medication, and the information potentially qualifying as an AER. This must then be filed with the Food and Drug Administration, which will lead to reevaluation of the product’s safety.”

The Rottenstein Law Group maintains a Web site to provide comprehensive information to the public about specific dangerous drugs and defective medical products. Those who wish to learn about particular harmful medications or faulty devices will be able to find all relevant information at the site, which is updated regularly as new information becomes available. The Web site URL is http://www.rotlaw.com.

 About THE ROTTENSTEIN LAW GROUP

The Rottenstein Law Group is a New York-based law firm that represents clients in mass tort actions, including Fosamax lawsuits, Paxil lawsuits, Zoloft lawsuits, DePuy hip replacement lawsuits, and many others. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients in consumer product injury, mass tort, and class action lawsuits in a compassionate manner. http://www.rotlaw.com

Contact:

The Rottenstein Law Group, LLP

Rochelle Rottenstein, Esq.

1259 Veeder Drive

Hewlett NY 11557

(212) 933-9500 (office phone)

(212) 933-9980 (facsimile)

rochelle(at)rotlaw(dot)com

 

Read more: http://www.digitaljournal.com/pr/400516#ixzz1W2Duzwfy

 

 

Related articles

• Rottenstein Law Group Anticipates Prompt Formation of Leadership Committees in Federal Multidistrict Litigation of DePuy Pinnacle Lawsuits (earlsview.com)
• Rottenstein Law Group Curious About Reserves Set Aside by Johnson & Johnson for DePuy Victims (earlsview.com)
• Commenting now open on pharmaceutical company Facebook pages (2020health.wordpress.com)
• Facebook Forces Drug Companies To Open Their Walls (allfacebook.com)
• Facebook stops letting drug companies disable their Walls (zdnet.com)
• 8 Tips for Healthcare & Pharmaceutical Companies on Facebook (bjconquest.com)
• Dear Facebook, My HooHoo Hurts: Facebook No Longer Protects Big Pharma From Public Comment (nytimes.com)
• Facebook stops drugmakers’ comment feature (sfgate.com)
• Facebook stops drugmakers’ comment feature (sfgate.com)
• Pharmas will monitor Facebook posts after site changes pharmas’ Wall policy (medcitynews.com)